Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Demetrius Albanes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8330-4293; OpenAlex author ID A5027838123, A5044923844; NIH RePORTER profile ID 9414784. Sources: OpenAlex.

Their work

Papers
47 (first author 0, last author 1)
Trials
0
Grants
1
Labs led
0
Collaborators
64
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 5 papers · 2014: 5 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 5 papers · 2021: 4 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers, 1 grant · 2026: 5 papers

Papers 47

  1. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  2. Metabolomic profiling of genotype-derived ABO blood group, secretor status, and Lewis antigens and association with pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1093/aje/kwag055↗
  3. Lipid biomarkers of habitual alcohol intake and associations with pancreatic cancer risk. Co-author DOI 10.1093/jnci/djaf288↗
  4. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  5. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  6. Association between prediagnostic serum metabolites and pancreatic ductal adenocarcinoma risk in two prospective cohorts. Co-author DOI 10.1002/ijc.35479↗
  7. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  8. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. Co-author DOI 10.1371/journal.pmed.1004590↗
  9. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  10. Lipidomics and pancreatic cancer risk in two prospective studies. Co-author DOI 10.1007/s10654-023-01014-3↗
  11. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  12. Nested Case-Control Studies Investigating Serum Perfluorooctanoate and Perfluorooctane Sulfonate Levels and Pancreatic Ductal Adenocarcinoma in Two Cohorts. Co-author DOI 10.1289/ehp13208↗
  13. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  14. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  15. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  16. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  17. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  18. Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study. Co-author DOI 10.1136/gutjnl-2019-319811↗
  19. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  20. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  21. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  22. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  23. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  24. Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Co-author DOI 10.1093/carcin/bgy072↗
  25. Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking? Co-author DOI 10.1158/1055-9965.epi-16-0891↗
  26. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  27. Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. Co-author DOI 10.1093/aje/kwv041↗
  28. Vitamin D metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0117574↗
  29. Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. Co-author DOI 10.1371/journal.pone.0129983↗
  30. Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies. Co-author DOI 10.1007/s10552-014-0409-z↗
  31. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  32. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Co-author DOI 10.1093/annonc/mdu019↗
  33. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2012-303477↗
  34. Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancre… Co-author PMID 25379135↗
  35. A prospective analysis of telomere length and pancreatic cancer in the alpha-tocopherol beta-carotene cancer (ATBC) prevention study. Co-author DOI 10.1002/ijc.28272↗
  36. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Co-author DOI 10.1007/s10552-012-0078-8↗
  37. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Co-author DOI 10.1007/s10552-012-0138-0↗
  38. Seropositivity to Helicobacter pylori and risk of pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-13-0680↗
  39. An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. Co-author DOI 10.1371/journal.pone.0072311↗
  40. Intake of fruits and vegetables and risk of pancreatic cancer in a pooled analysis of 14 cohort studies. Co-author DOI 10.1093/aje/kws027↗
  41. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Co-author DOI 10.1093/carcin/bgs151↗
  42. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Last author DOI 10.1158/0008-5472.can-11-2950↗
  43. Coffee, tea, and sugar-sweetened carbonated soft drink intake and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Co-author DOI 10.1158/1055-9965.epi-11-0945-t↗
  44. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies. Co-author DOI 10.1093/jnci/djr431↗
  45. Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: a prospective stud… Co-author DOI 10.1158/0008-5472.can-10-2573↗
  46. Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Co-author DOI 10.1158/1055-9965.epi-10-1024↗
  47. Mitochondrial DNA copy number and pancreatic cancer in the alpha-tocopherol beta-carotene cancer prevention study. Co-author DOI 10.1158/1940-6207.capr-11-0002↗

Grants 1

  1. Physical Activity, Energy Balance, and Cancer ZIACP010197↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rachael Z. Stolzenberg‐Solomon · 22 shared papers, 1 shared grant, 2011–2026 · strength 3.05
  2. Stephanie J. Weinstein · 14 shared papers, 2011–2026 · strength 1.57
  3. Ting Zhang · 4 shared papers, 2023–2026 · strength 1.08
  4. Sabine Naudin · 2 shared papers, 2023–2026 · strength 0.52
  5. Herbert Yu · 3 shared papers, 2013–2025 · strength 0.49
  6. Joshua Neil Sampson · 2 shared papers, 2020–2023 · strength 0.34
  7. Paloma R. Mitra · 1 shared paper, 2026 · strength 0.32
  8. Eric J. Jacobs · 6 shared papers, 2011–2017 · strength 0.23
  9. Debra T. Silverman · 5 shared papers, 2011–2017 · strength 0.22
  10. Mark P. Purdue · 1 shared paper, 2023 · strength 0.20
  11. Michaël Pollak · 4 shared papers, 2011–2017 · strength 0.19
  12. Letícia Nogueira · 3 shared papers, 2014–2017 · strength 0.17
  13. Kristin E. Anderson · 5 shared papers, 2011–2018 · strength 0.14
  14. Charles S. Fuchs · 5 shared papers, 2011–2014 · strength 0.11
  15. Thomas E. Rohan · 4 shared papers, 2011–2014 · strength 0.09
  16. Piet A. van den Brandt · 4 shared papers, 2011–2014 · strength 0.09
  17. Leslie Bernstein · 4 shared papers, 2011–2014 · strength 0.09
  18. Stephanie A. Smith‐Warner · 4 shared papers, 2011–2014 · strength 0.09
  19. Eric J. Duell · 2 shared papers, 2013–2018 · strength 0.07
  20. Wei Zheng · 2 shared papers, 2013–2018 · strength 0.07
  21. Xiao‐Ou Shu · 2 shared papers, 2013–2018 · strength 0.07
  22. Laufey Thora Amundadottir · 2 shared papers, 2013–2018 · strength 0.07
  23. Gloria M. Petersen · 2 shared papers, 2013–2018 · strength 0.07
  24. Li Jiao · 2 shared papers, 2011–2014 · strength 0.07
  25. Anita Koushik · 3 shared papers, 2012–2014 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.